| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CRBP | Common Stock, par value $0.0001 per share | Options Exercise | $237K | +16.8K | +19.94% | $14.10 | 101K | Jun 14, 2024 | Direct | F1 |
| transaction | CRBP | Common Stock, par value $0.0001 per share | Sale | -$844K | -16.8K | -16.63% | $50.17 | 84.4K | Jun 14, 2024 | Direct | F1, F2, F3 |
| transaction | CRBP | Common Stock, par value $0.0001 per share | Options Exercise | $53.2K | +12.5K | +14.8% | $4.26 | 96.9K | Jun 14, 2024 | Direct | F1 |
| transaction | CRBP | Common Stock, par value $0.0001 per share | Sale | -$626K | -12.5K | -12.89% | $50.17 | 84.4K | Jun 14, 2024 | Direct | F1, F2, F3 |
| transaction | CRBP | Common Stock, par value $0.0001 per share | Options Exercise | $280K | +9.33K | +11.06% | $30.00 | 93.7K | Jun 17, 2024 | Direct | F1 |
| transaction | CRBP | Common Stock, par value $0.0001 per share | Sale | -$430K | -9.33K | -9.96% | $46.02 | 84.4K | Jun 17, 2024 | Direct | F1, F2, F4 |
| transaction | CRBP | Common Stock, par value $0.0001 per share | Options Exercise | $7.54K | +1.77K | +2.1% | $4.26 | 86.2K | Jun 17, 2024 | Direct | F1 |
| transaction | CRBP | Common Stock, par value $0.0001 per share | Sale | -$81.5K | -1.77K | -2.05% | $46.02 | 84.4K | Jun 17, 2024 | Direct | F1, F2, F4 |
| transaction | CRBP | Common Stock, par value $0.0001 per share | Options Exercise | $350K | +11.7K | +13.82% | $30.00 | 96.1K | Jun 18, 2024 | Direct | F1 |
| transaction | CRBP | Common Stock, par value $0.0001 per share | Sale | -$493K | -11.7K | -12.14% | $42.24 | 84.4K | Jun 18, 2024 | Direct | F1, F2, F5 |
| transaction | CRBP | Common Stock, par value $0.0001 per share | Options Exercise | $25K | +1.77K | +2.1% | $14.10 | 86.2K | Jun 18, 2024 | Direct | F1 |
| transaction | CRBP | Common Stock, par value $0.0001 per share | Sale | -$74.8K | -1.77K | -2.05% | $42.24 | 84.4K | Jun 18, 2024 | Direct | F1, F2, F5 |
| transaction | CRBP | Common Stock, par value $0.0001 per share | Options Exercise | $9.89K | +2.32K | +2.75% | $4.26 | 86.7K | Jun 18, 2024 | Direct | F1 |
| transaction | CRBP | Common Stock, par value $0.0001 per share | Sale | -$98.1K | -2.32K | -2.68% | $42.24 | 84.4K | Jun 18, 2024 | Direct | F1, F2, F5 |
| transaction | CRBP | Common Stock, par value $0.0001 per share | Sale | -$303K | -7.18K | -8.51% | $42.24 | 77.2K | Jun 18, 2024 | Direct | F1, F2, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CRBP | Options to purchase common stock | Options Exercise | $0 | -16.8K | -33.89% | $0.00 | 32.8K | Jun 14, 2024 | Common Stock | 16.8K | $14.10 | Direct | F6 |
| transaction | CRBP | Options to purchase common stock | Options Exercise | $0 | -12.5K | -18.83% | $0.00 | 53.8K | Jun 14, 2024 | Common Stock | 12.5K | $4.26 | Direct | F7 |
| transaction | CRBP | Options to purchase common stock | Options Exercise | $0 | -9.33K | -44.44% | $0.00 | 11.7K | Jun 17, 2024 | Common Stock | 9.33K | $30.00 | Direct | F8 |
| transaction | CRBP | Options to purchase common stock | Options Exercise | $0 | -1.77K | -3.29% | $0.00 | 52.1K | Jun 17, 2024 | Common Stock | 1.77K | $4.26 | Direct | F7 |
| transaction | CRBP | Options to purchase common stock | Options Exercise | $0 | -11.7K | -100% | $0.00* | 0 | Jun 18, 2024 | Common Stock | 11.7K | $30.00 | Direct | F8 |
| transaction | CRBP | Options to purchase common stock | Options Exercise | $0 | -1.77K | -5.39% | $0.00 | 31.1K | Jun 18, 2024 | Common Stock | 1.77K | $14.10 | Direct | F6 |
| transaction | CRBP | Options to purchase common stock | Options Exercise | $0 | -2.32K | -4.46% | $0.00 | 49.7K | Jun 18, 2024 | Common Stock | 2.32K | $4.26 | Direct | F7 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | This amount includes 73,947 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025. |
| F2 | This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. |
| F3 | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.27 to $52.23 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| F4 | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.0 to $49.38 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| F5 | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.75 to $43.69 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| F6 | The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023. |
| F7 | The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024. |
| F8 | The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested. |